We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Nov 2, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The company develops and markets end-to-end automation solutions for the medication use process.
Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, weak gross margin scenario is a matter of concern. We believe the company’s strategies including portfolio expansion, acquisitions and penetration into the medication adherence market continue to drive expenses. Meanwhile, expenses related to the recently launched XT series have been exerting pressure on the bottom line.
Omnicell’s lowering of the high end of the full-year 2017 adjusted revenue guidance is reflective of the fact that the overall weakness will continue. A tough competitive landscape also acts as a dampener.
Over the last three months, Omnicell’s shares have been trading below the broader industry. As per the latest share price movement, the stock has lost 1%, significantly underperforming the broader industry’s addition of 2.9%.
On a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all business lines in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Over the recent past, Omnicell has been observed to gain consistently from series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.
Zacks Rank & Key Picks
Omnicell has a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 87.6% over the last year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 18% in the last year.
Intuitive Surgical has a long-term expected earnings growth rate of 9.1%. The stock has gained 67.6% last year.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Omnicell's Higher Investments Drive Costs, Competition Rife
On Nov 2, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The company develops and markets end-to-end automation solutions for the medication use process.
Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, weak gross margin scenario is a matter of concern. We believe the company’s strategies including portfolio expansion, acquisitions and penetration into the medication adherence market continue to drive expenses. Meanwhile, expenses related to the recently launched XT series have been exerting pressure on the bottom line.
Omnicell’s lowering of the high end of the full-year 2017 adjusted revenue guidance is reflective of the fact that the overall weakness will continue. A tough competitive landscape also acts as a dampener.
Over the last three months, Omnicell’s shares have been trading below the broader industry. As per the latest share price movement, the stock has lost 1%, significantly underperforming the broader industry’s addition of 2.9%.
On a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all business lines in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Over the recent past, Omnicell has been observed to gain consistently from series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.
Zacks Rank & Key Picks
Omnicell has a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 87.6% over the last year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 18% in the last year.
Intuitive Surgical has a long-term expected earnings growth rate of 9.1%. The stock has gained 67.6% last year.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>